ALNYLAM PHARMACEUTICALS, INC. (ALNY) vs AMGEN INC (AMGN)
Side-by-side comparison from SEC filings: latest annual financials, insider activity and institutional ownership.
| Metric | ALNY | AMGN |
|---|---|---|
| Sector | Health Care | Health Care |
| Latest fiscal year | FY2025 | FY2025 |
| Revenue | $3.71B | $36.75B |
| Revenue growth (YoY) | ▲ 65.2% | ▲ 10.0% |
| Net income | $313.75M | $7.71B |
| Gross margin | 81.8% | 67.2% |
| Diluted EPS | $2.33 | $14.23 |
| Insider net (6 mo) | +15.8K sh • 2 sells • 0 buys | +15.3K sh • 5 sells • 0 buys |
| Institutional owners | 46 | 46 |
| Institutional value held | $29.35B | $113.58B |
| Next earnings (est.) | Around Oct 29, 2026 | Nov 3, 2026 |
Figures from each company's SEC filings (latest reported fiscal year; fiscal calendars may differ). Next-earnings dates are estimates from historical filing patterns.
About ALNYLAM PHARMACEUTICALS, INC. (ALNY)
Alnylam Pharmaceuticals is a global commercial-stage biopharmaceutical company that develops novel therapeutics based on RNA interference (RNAi), a naturally occurring biological pathway used to silence disease-causing genes by targeting messenger RNA before… Read more →
About AMGEN INC (AMGN)
Amgen Inc. is a global biotechnology company, incorporated in California in 1980 and reincorporated in Delaware in 1987, that discovers, develops, manufactures, and delivers innovative medicines targeting areas of high unmet medical need, operating as a… Read more →
Source: SEC EDGAR.